The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
about
Incretin-Based Therapy for Prevention of Diabetic Vascular ComplicationsDPP4 in DiabetesDipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protectionGLP-1 and cardioprotection: from bench to bedsideRemote ischaemic conditioning in the context of type 2 diabetes and neuropathy: the case for repeat application as a novel therapy for lower extremity ulcerationSitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoformsOral Administration of Sitagliptin Activates CREB and Is Neuroprotective in Murine Model of Brain TraumaGlucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemLeft ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study.Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrixDiabetes: impaired damage controlLoss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patientsThe dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.Evaluation of Anti Cancer Effects of DPP-4 Inhibitors in Colon Cancer- An Invitro StudyCardiovascular biology of the incretin system.Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010, 2014) Launch of New DrugsCardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted ratsTherapy in the early stage: incretins.Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese ratsCardiovascular effects of dipeptidyl peptidase-4 inhibitors.Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury.Cardiovascular effects of incretin-based therapies.Cardioprotective effects of incretin during ischaemia-reperfusion.The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.The impact of current and novel anti-diabetic therapies on cardiovascular risk.Cardiovascular effects of gliptins.The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives.Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system.Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach.Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury.Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1
P2860
Q26765470-2BBC8394-60D0-4BFA-812A-CE3359810C3EQ26797335-3BF75CAC-5F4A-4DE6-A811-41017B3556FEQ27011819-0AAEA29C-D7A9-4D31-A193-3CB1F7096B2AQ27024984-C2044BB3-8AC2-4EAC-97E3-4A4C5978D1CFQ28078462-ED6B59CA-8D59-480F-B509-04A8C0BF3156Q28535415-29B79033-8E3F-4B94-A90C-A5BF2D86D352Q28591252-A2FA6B37-D253-493B-82AB-1602AF847BBBQ33603384-68DD16D5-BB35-447B-B309-99CE1DF5E2C3Q33660548-8FEBC248-5B33-4EC1-860F-F66F57643DF8Q34062829-D6EE30AF-EF98-467C-9D9D-F70E225EE07CQ34283308-AFB1BCD4-04FC-4DE1-8D4D-B6CF1440FC13Q35132702-F93BAF17-32E9-4E92-B37A-DAC3045CCD8DQ35587364-8364F4AB-6991-4D57-838C-5468E35E1CF4Q35654597-5959BA07-6765-4F36-88E3-00ACFEC4919AQ36381927-135144D7-66CB-4D9B-B440-639E365684BEQ36466692-AC450789-EACA-4AD2-811C-813B4BF1C6EEQ36476438-3FE10557-6E80-41F2-9E99-B65E6E95068AQ36484283-1656A881-59CC-4082-8261-5C5BB7AED0B9Q36638899-5D6F5568-1C11-4B0E-92D0-E09710E9B9B0Q36649277-471006CC-C81A-4BC7-96D8-1BDEABA514D3Q36691245-0FBAF0CA-4766-4234-9F7E-54D914AFC812Q36783865-B1253321-A18D-4622-8DFC-5875644272CDQ36868364-AFF2B579-0E6E-454E-8E18-A30F104352B1Q36946065-FF4F693F-3A0C-4D22-94F0-D82D838219B7Q37079289-67949CCA-101F-4782-9909-398A376B69ABQ37274296-EED4D434-B79D-414C-890D-5AC226E7369DQ37825946-002A7826-E164-444C-A6C6-BA4D6CE6E4DDQ37869699-B2996E39-4A36-43B2-8B45-1FA31D8A1F49Q37900151-A370291E-4845-4206-B0E4-AC7F1E292BF1Q37926558-EBF02507-3D59-4266-BFD7-AC1849FFE776Q37977336-6A05939C-C211-4FB7-A272-6D30701DD5A6Q38002006-486594D8-A2A2-45EB-9255-8E95B9674989Q38036769-4F2B83F5-8E9C-4200-9136-0749BCD85233Q38062033-5F22C300-7893-4F9D-BAF1-309BBFC8F58BQ38072259-648AB38E-ED27-4778-91E1-E5C487C98925Q38104293-B338A139-DEC0-4235-BFFF-6ADDCE3A48A5Q38118157-EE559C75-34E0-4DF2-A686-63C0856ED377Q38119146-04046908-5DF2-478F-87D0-91A17F562653Q38137849-27641A0C-909A-4449-9FAC-5CB86CA5168BQ38177382-3879AD36-3BA2-49D9-A0F4-C8F321F12158
P2860
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The myocardial infarct size-li ...... is partially dependent on PKA.
@en
The myocardial infarct size-li ...... is partially dependent on PKA.
@nl
type
label
The myocardial infarct size-li ...... is partially dependent on PKA.
@en
The myocardial infarct size-li ...... is partially dependent on PKA.
@nl
prefLabel
The myocardial infarct size-li ...... is partially dependent on PKA.
@en
The myocardial infarct size-li ...... is partially dependent on PKA.
@nl
P2093
P2860
P1476
The myocardial infarct size-li ...... is partially dependent on PKA.
@en
P2093
Congfang Zhang
Jose R Perez-Polo
Kyle T Keyes
Yochai Birnbaum
P2860
P304
P356
10.1152/AJPHEART.00867.2009
P577
2010-03-05T00:00:00Z